On February 27, 2019 Helix BioPharma Corp. (TSX: HBP), (FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, reported that together with the Moffitt Cancer Center ("Moffitt"), a poster entitled "Improving survival in pancreatic cancer using Doxorubicin in combination with L-DOS47" will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) ("AACR") Annual Meeting 2019 which is taking place on March 29 – April 3, 2019 at the Georgia World Congress Center, Atlanta, Georgia, USA.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The presentation will describe the use of a preclinical pancreatic mouse model to study the effects of LDOS47 alone or in combination therapies. This model was generated by modifying a mouse pancreatic cancer cell line (Panc02) to express the human ceacam6 antigen that is recognized by L-DOS47. The model is designed to be used for monotherapy L-DOS47 efficacy studies and for combination studies with various agents, including immunotherapies. In addition, to therapeutic studies, the model may also be helpful in studying the effects of L-DOS47 in modifying tumor pH and the tumor immune environment. The presentation will describe the development of the cell line, generation of tumor grafts, and show responses to L-DOS47 in combination with doxorubicin treatments. The usefulness of the model, including difficulties of this model, will also be described. This work is part of an on-going collaboration with Moffitt and is being performed to support the clinical development of L-DOS47 and the DOS47 platform.
"I would like to thank Dr. Robert (Bob) Gillies and the Moffitt team on leading this work" said Heman Chao, Helix’s Chief Executive Officer. "Following on the excellent safety and tolerability results from the Phase I monotherapy lung cancer study in Poland and continuing good progress made with the U.S. Phase I LDOS47 combination study with pemetrexed and carboplatin, we are very excited to launch the pancreatic program and expand the clinical application of L-DOS47."
Presentation details are as follows:
Session Category: Experimental and Molecular Therapeutics
Session Title: Cellular Responses to Anticancer Agents 1: The Microenvironment and Metastasis
Session Date and Time: Monday April 1, 2019 from 8:00 AM-12:00 PM
Location: Georgia World Congress Center, Exhibit Hall B.